The 32-Point Gap: Donor Egg IVF at Ages 43–44 Delivers a 46% Live Birth Rate — Three Times Higher Than Own-Egg Cycles

A Number That Should Be on Every Clinic's Front Page

Fourteen percent. That is the live birth rate from frozen non-donor IVF for women aged 43–44, measured across 2022 and again confirmed in 2023. The number barely moved between years — 14.0% in 2022, 14.1% in 2023 — which tells you something important: this is not statistical noise. It is a structural ceiling imposed by egg quality at that age.

Now consider what happens when the egg source changes. Frozen donor-egg IVF for the same 43–44 age cohort produces a 46% live birth rate. Same uterus. Same clinic protocols. Same frozen transfer procedure. The only variable is whose eggs produced the embryos.

That is a 32-percentage-point gap — and it is the most consequential number in fertility medicine that most patients encounter only after multiple failed cycles.

The national average success rate you see advertised by most clinics is a blended figure. It averages across all ages, all protocols, donor and non-donor together. A clinic serving a younger patient population will show a better blended rate than one serving a similar mix of older patients, even if the actual clinical quality is identical. The aggregate number obscures the very stratification that determines whether a specific patient succeeds. Feralyx's age-stratified data is built to cut through exactly this problem.

Why the Age Cliff Is Steeper Than Most Patients Expect

The under-35 frozen non-donor live birth rate sits at 50.5%. The 35–37 cohort, using their own frozen eggs, achieves 42.8% as of 2024. That is a gap of roughly 8 percentage points across what could be anywhere from 3 to 7 years of age — a relatively gradual decline.

Then something changes at the far end of the reproductive window. From 35–37 at 42.8%, to 43–44 at 14.1% — that is a 28.7 percentage point collapse across a span of roughly 6 to 9 years. The decline is not linear. It accelerates sharply after the late 30s, driven by a well-documented rise in chromosomal abnormality rates in eggs. By age 43, the majority of eggs retrieved in a typical stimulation cycle carry aneuploidies that prevent viable implantation. Preimplantation genetic testing can filter those embryos out, but it cannot manufacture chromosomally normal eggs that were not produced in the first place.

This is not a clinical failure — it is biology. And the data reflects it with unusual precision: a 14% rate held to within one-tenth of a percentage point across two consecutive years of measurement. When you see that kind of temporal stability in an outcome metric, you are looking at a floor, not a fluctuation.

What most women approaching 43–44 are never shown — at least not in the first consultation, and often not until after the second or third failed retrieval cycle — is that the 46% donor-egg figure is available to them now. Not in the future, not contingent on another retrieval attempt. The uterine environment at 43–44 is demonstrably capable of sustaining pregnancies at rates that rival women nearly a decade younger. The constraint is almost entirely upstream of implantation.

What 46% Actually Means as a Decision Number

Forty-six percent is not just better than 14%. It is, in statistical terms, a different outcome universe.

At 14%, a patient pursuing three own-egg frozen transfer cycles has a cumulative probability of approximately 36% — assuming independent cycles, which overstates the true figure since the same egg quality limitations apply to each attempt. At 46% per cycle, a single donor-egg transfer cycle surpasses the three-cycle cumulative probability of own-egg transfers by a meaningful margin.

The financial arithmetic compounds this. A single frozen embryo transfer cycle ranges from roughly $3,000 to $6,000 for the transfer itself, excluding retrieval costs if the clinic builds a fresh batch. But if a patient has already banked donor embryos — through an embryo donation program, a shared-risk donor arrangement, or a frozen donor egg bank — the per-cycle cost structure changes considerably. Three own-egg retrieval-and-transfer cycles at $15,000–$25,000 each can approach $60,000–$75,000 in cumulative spending before a live birth, against a probability structure that tops out around 36–40%. A donor-egg path at 46% per transfer cycle, even at a higher per-cycle cost, is often cheaper per expected live birth by the time the math resolves.

Clinics rarely present this arithmetic up front. The framing tends to favor attempting own-egg retrieval first — which is understandable medically, since uterine testing, ovarian reserve assessment, and stimulation response data are all diagnostically useful. But the framing also reflects clinic economics: retrieval cycles are significantly more expensive than transfers, and the revenue model favors retrieval attempts. Understanding the underlying rate structure before entering that sequence is worth considerable money.

The 35–37 Benchmark and What It Reveals About Uterine Biology

The 42.8% figure for women aged 35–37 using frozen non-donor eggs in 2024 carries a second implication that the raw number does not immediately surface.

The donor-egg success rate for women aged 43–44 — 46% — is not materially different from the own-egg success rate for women aged 35–37. They are, within the range of sampling variance, functionally equivalent. A 43-year-old using donor eggs performs at the same statistical level as a 36-year-old using her own eggs.

This is the analytical claim that national averages systematically hide: donor egg use at 43–44 does not merely improve outcomes. It compresses approximately eight years of biological age in a single clinical decision, closing 73% of the gap between a 43-year-old's own-egg results and the under-35 benchmark of 50.5%.

The implication for clinical counseling is significant. If the uterus at 43 supports a 46% live birth rate — essentially the same as it does at 36 — then the argument that patients should "try with their own eggs first" because uterine receptivity declines with age is not supported by this outcome data. The uterus at 43–44, in the context of donor embryo transfers, is performing near its biological ceiling. The ceiling is set by egg quality, not endometrial function.

This matters because a common patient fear around donor eggs involves the assumption that something is "wrong" with their body — that using donor eggs is a workaround for a failing system. The data does not support that framing. The system works. The supply chain has a constraint. Those are different problems with different solutions.

You can explore the full age-stratified outcome data at Feralyx to see how these rates pattern across different cycle types, age bands, and year-over-year trends.

The Insurance Mandate Variable

Most fertility patients in the United States are navigating these decisions in the absence of insurance coverage. As of 2024, 19 states have fertility insurance mandates, but the scope and depth of those mandates varies enormously. Some cover IVF broadly; others exclude donor egg cycles; others impose cycle limits that effectively cap coverage before a patient aged 43–44 can accumulate enough transfer attempts to hit the 46% threshold.

The insurance exclusion of donor egg cycles is particularly consequential for older patients. A mandate that covers three own-egg IVF cycles but excludes donor egg cycles is, for a 43-year-old patient, providing coverage for the 14% path while leaving the 46% path entirely out of pocket. That is not a neutral policy design — it selectively funds the statistically inferior option while leaving the superior one inaccessible to patients who cannot absorb $20,000–$35,000 in out-of-pocket donor egg costs.

Whether a patient lives in a mandate state, and whether that mandate covers donor cycles, is therefore a variable that interacts directly with the outcome data above. A patient in Illinois — which has one of the broader mandates — faces a fundamentally different financial decision architecture than one in Texas, which has no mandate at all. The clinical data is the same across state lines. The financial access to the higher-probability path is not.

Feralyx models these mandate interactions alongside success rates so patients can see how their specific coverage situation intersects with age-cohort outcome data, rather than looking at either piece in isolation.

How to Use This Data in an Actual Consultation

The practical use of these numbers is not to arrive at a clinic appointment having pre-decided on donor eggs. It is to ask better questions.

Any clinic performing IVF should be able to produce their own age-stratified, donor-versus-non-donor live birth rates. The CDC's ART database, maintained annually, requires all SART-member clinics to report outcomes at this level of granularity. A clinic that presents only blended success rates, or that hedges on providing age-stratified data, is either not analyzing their own outcomes carefully or is choosing not to show you the numbers that matter most to your situation.

Specific questions worth asking before committing to an own-egg retrieval cycle at 43–44:

What is your clinic's live birth rate for frozen non-donor transfers in the 43–44 age band, averaged over the last three report years? If that number is not close to the 14% national figure, understand why — either they are seeing something unusual in their population, or their reporting may be incomplete.

What is your clinic's donor-egg frozen transfer rate for the same age group? If they do not offer donor egg cycles in-house, they should be referring to programs that do, and they should know the outcomes.

What is your AMH and AFC, and what do those numbers suggest about the expected yield from a stimulation cycle? If the anticipated retrieval is two to four eggs, and chromosomal testing is likely to leave zero or one viable blastocyst, the expected value of that cycle is substantially below the national 14% average.

The data reveals a decision structure. Using it requires treating fertility medicine the way any expensive, probabilistic process should be treated: with explicit probability estimates, cost-per-outcome math, and willingness to challenge the default clinical pathway when the numbers justify it.

For women aged 43–44, the numbers justify the conversation.

Related Analysis

Other Smart Technology Investments tools that bear on this decision:

• Toravine: medicare, plan, advantage
• DriveDecision: vehicle, car, tco
• Kavivero: mortgage refinance, refinance break even, cash out refi
• Fluvenar: flood, fema, insurance